Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling
Abstract Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally invasive procedures. Here, we describe our lo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-55456-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559238669762560 |
|---|---|
| author | David Kim Chad M. Vanderbilt Soo-Ryum Yang Subhiksha Nandakumar Khedoudja Nafa Rusmir Feratovic Natasha Rekhtman Ivelise Rijo Jacklyn Casanova Anita Yun A. Rose Brannon Michael F. Berger Marc Ladanyi Oscar Lin Maria E. Arcila |
| author_facet | David Kim Chad M. Vanderbilt Soo-Ryum Yang Subhiksha Nandakumar Khedoudja Nafa Rusmir Feratovic Natasha Rekhtman Ivelise Rijo Jacklyn Casanova Anita Yun A. Rose Brannon Michael F. Berger Marc Ladanyi Oscar Lin Maria E. Arcila |
| author_sort | David Kim |
| collection | DOAJ |
| description | Abstract Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally invasive procedures. Here, we describe our long-term experience in profiling cytology samples with an in-depth assessment of the performance, quality metrics, biomarker identification capabilities, and potential pitfalls. We highlight the impact of several optimization strategies to maximize performance with 4,871 prospectively sequenced clinical cytology samples tested by MSK-IMPACTTM. Special emphasis is given to the use of residual supernatant cell-free DNA (ScfDNA) as a valuable source of tumor DNA. Overall, cytology samples are similar in performance to surgical samples in identifying clinically relevant genomic alterations, achieving success rates up to 93% with full optimization. While cell block (CB) samples have excellent performance overall, low-level cross-contamination is identified in a small proportion of cases (4.7%), a common pitfall intrinsic to the processing of paraffin blocks, suggesting that more stringent precautions and processing modifications should be considered in quality control initiatives. By contrast ScfDNA samples have negligible contamination. Finally, ScfDNA testing exclusively used as a rescue strategy, delivered successful results in 71% of cases where tumor tissue from CB was depleted. |
| format | Article |
| id | doaj-art-bd3138049d8840d3b8a8a220a7c9c6e7 |
| institution | Kabale University |
| issn | 2041-1723 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-bd3138049d8840d3b8a8a220a7c9c6e72025-01-05T12:39:43ZengNature PortfolioNature Communications2041-17232025-01-0116111110.1038/s41467-024-55456-8Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profilingDavid Kim0Chad M. Vanderbilt1Soo-Ryum Yang2Subhiksha Nandakumar3Khedoudja Nafa4Rusmir Feratovic5Natasha Rekhtman6Ivelise Rijo7Jacklyn Casanova8Anita Yun9A. Rose Brannon10Michael F. Berger11Marc Ladanyi12Oscar Lin13Maria E. Arcila14Department of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Pathology & Laboratory Medicine, Memorial Sloan Kettering Cancer CenterAbstract Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally invasive procedures. Here, we describe our long-term experience in profiling cytology samples with an in-depth assessment of the performance, quality metrics, biomarker identification capabilities, and potential pitfalls. We highlight the impact of several optimization strategies to maximize performance with 4,871 prospectively sequenced clinical cytology samples tested by MSK-IMPACTTM. Special emphasis is given to the use of residual supernatant cell-free DNA (ScfDNA) as a valuable source of tumor DNA. Overall, cytology samples are similar in performance to surgical samples in identifying clinically relevant genomic alterations, achieving success rates up to 93% with full optimization. While cell block (CB) samples have excellent performance overall, low-level cross-contamination is identified in a small proportion of cases (4.7%), a common pitfall intrinsic to the processing of paraffin blocks, suggesting that more stringent precautions and processing modifications should be considered in quality control initiatives. By contrast ScfDNA samples have negligible contamination. Finally, ScfDNA testing exclusively used as a rescue strategy, delivered successful results in 71% of cases where tumor tissue from CB was depleted.https://doi.org/10.1038/s41467-024-55456-8 |
| spellingShingle | David Kim Chad M. Vanderbilt Soo-Ryum Yang Subhiksha Nandakumar Khedoudja Nafa Rusmir Feratovic Natasha Rekhtman Ivelise Rijo Jacklyn Casanova Anita Yun A. Rose Brannon Michael F. Berger Marc Ladanyi Oscar Lin Maria E. Arcila Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling Nature Communications |
| title | Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling |
| title_full | Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling |
| title_fullStr | Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling |
| title_full_unstemmed | Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling |
| title_short | Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling |
| title_sort | maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling |
| url | https://doi.org/10.1038/s41467-024-55456-8 |
| work_keys_str_mv | AT davidkim maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT chadmvanderbilt maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT sooryumyang maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT subhikshanandakumar maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT khedoudjanafa maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT rusmirferatovic maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT natasharekhtman maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT iveliserijo maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT jacklyncasanova maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT anitayun maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT arosebrannon maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT michaelfberger maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT marcladanyi maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT oscarlin maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling AT mariaearcila maximizingtheclinicalutilityandperformanceofcytologysamplesforcomprehensivegeneticprofiling |